HVR Cardio

Tietoa

HVR Cardio develops CathHELIX, a catheter-based device for mitral valve repair that has received FDA Breakthrough Device Designation. The device reduces the mitral annulus and deploys a self-securing ring to restore native leaflet function, offering a minimally invasive treatment for mitral regurgitation with Series B funding secured.